Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Study of Endostar Injection Concomitant With SOX Protocols to Treat Advanced Gastric Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02008422
Recruitment Status : Unknown
Verified August 2013 by Tang Xushan, Xinjiang Medical University.
Recruitment status was:  Active, not recruiting
First Posted : December 11, 2013
Last Update Posted : December 11, 2013
Sponsor:
Information provided by (Responsible Party):
Tang Xushan, Xinjiang Medical University

Brief Summary:
The primary objectives of this control, single-center clinical study of EndostarTM Injection with/without SOX protocols to treat advanced gastric cancer were to evaluate the clinical response rate of Endostar injection concomitant with SOX on patients with advanced gastric cancer, observe the progression-free survival time (PFS) of tumor and evaluate the safety and tolerance of Endostar injection, while the secondary objectives were to observe the influence of Endostar injection on chemotherapy-induced adverse reactions and evaluate the overall survival time of EndostarTM injection concomitant with SOX on patients with advanced gastric cancer by evaluating the response rate (RR) clinical benefit rate (CBR), progression-free survival (PFS) and overall survival (OS).

Condition or disease Intervention/treatment Phase
Gastric Cancer Drug: Oxaliplatin Drug: Gimeracil and Oteracil Potassium Capsule Drug: Endostar injection Phase 3

Detailed Description:

Multiple pre-clinical studies have indicated that in dozens of animal tumor models and human tumor-metastatic mice tumor models, the effective rate of Endostar was 47%~91% in daily dosage of 10~100mg/kg, and covered human commonly seen malignant tumors, such as lung cancer, gastric cancer, breast cancer, colorectal cancer, hepatic cancer, malignant melanoma and non-Hodgkin's lymphoma, etc.. The development and progression of gastric cancer was in association with angiogenesis. An animal research observed the influence of Endostar on tumor strains in nude mice with gastric cancer, and the results showed that tumor size shrunk rapidly and the expressions of VEGF, bFGF, VEGF-C, VEGFR-3, bcl-2 and PDGF decreased significantly after treatment in experimental group, demonstrating that Endostar could reduce angiogenesis, increase tumor cell apoptosis and inhibit tumor growth in gastric cancer. An investigation of small-sample Endostar concomitant with chemotherapy on patients with advanced gastric cancer primarily indicated the efficacy and feasibility of Endostar concomitant with chemotherapy in treating gastric cancer.

With the expanded application of Endostar in clinic, it also obtains certain effect in treating patients with lung cancer and colorectal cancer. The safety, efficacy, evaluation of relationship between benefit and risk in common or special population as well as the modified dosage of administration of Endostar in wide application should be further explored to provide sufficient scientifical basis for the safety, efficacy, applicable rule in special population and investigation of optimal administrative protocols for Endostar in wide application.

This control, single-center clinical study of EndostarTM Injection with/without SOX protocols to treat advanced gastric cancer was conducted to explore the feasibility, efficacy and safety of Endostar concomitant with SOX protocols, and to provide more evidence-based medical basis for the clinical application of Endostar.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open and Control Clinical Study of Endostar Injection Concomitant With SOX Protocols in Treating Advanced Gastric Cancer
Study Start Date : August 2013
Estimated Primary Completion Date : May 2016
Estimated Study Completion Date : August 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Oxaliplatin

Arm Intervention/treatment
Experimental: Oxaliplatin & Endostar injection
Oxaliplatin, 130 mg/m2 , iv, 3-4h, d1; Gimeracil and Oteracil Potassium Capsules, 40 mg/m2, po., Bid., d1-14; Endostar injection, 7.5 mg/m2/d, 2 mL/h continuous pumping into vein, d1-10; 21 d as a cycle.
Drug: Oxaliplatin
130mg/m2 , iv, 3-4h, d1, 21 d as a cycle.
Other Name: L-OHP

Drug: Gimeracil and Oteracil Potassium Capsule
40 mg/m2, po., Bid., d1-14, 21 d as a cycle.
Other Name: Tegafur Gimeracil Oteracil Potassium Capsule

Drug: Endostar injection
7.5 mg/m2/d, 2 mL/h continuous pumping into vein, d1-10, 21 d as a cycle.
Other Name: rh-Endostatin

Active Comparator: Oxaliplatin
Oxaliplatin, 130 mg/m2 , iv, 3-4h, d1; Gimeracil and Oteracil Potassium Capsules, 40 mg/m2, po., Bid., d1-14, 21 d as a cycle.
Drug: Oxaliplatin
130mg/m2 , iv, 3-4h, d1, 21 d as a cycle.
Other Name: L-OHP

Drug: Gimeracil and Oteracil Potassium Capsule
40 mg/m2, po., Bid., d1-14, 21 d as a cycle.
Other Name: Tegafur Gimeracil Oteracil Potassium Capsule




Primary Outcome Measures :
  1. Response rate (RR) [ Time Frame: The patients were followed up for 3 years. ]
    • Clinical RR=(CR+PR)/total cases×100%;
    • Complete remission (CR): all visible nidi disappeared;
    • Partial remission (PR): the decreased total length of diameter of baseline nidus≥30%;

  2. clinical benefit rate (CBR) [ Time Frame: The patients were followed up for 3 years. ]
    • Clinical CBR=(CR+PR+SD)/total cases×100%
    • Complete remission (CR): all visible nidi disappeared;
    • Stable disease (SD): the total length of diameter of baseline nidus decreased<that in PR or increased <that in PD.-Progressive disease (PD): the increased total length of diameter of baseline nidus≥30% or new nidus was presented;

  3. progression-free survival (PFS) [ Time Frame: The patients were followed up for 3 years ]
    PFS was from randomization to tumor progression or death.


Secondary Outcome Measures :
  1. overall survival (OS) [ Time Frame: The patients were followed up for 3 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age: 18~70 years;
  • Performance status (PS) of Eastern Cooperative Oncology Group (ECOG) was 0~1 or KPS scores were 60-100 scores;
  • Patients who were diagnosed with recurrent and metastatic advanced gastric cancer by histopathology and CT;
  • Patients who had more than 1 measurable nidus (common CT or MRI scanning ≥20 mm, spiral CT scanning ≥10 mm);
  • Patients who had no severe dysfunction of important organs, and were normal in blood routine test, hepatorenal function, electrolytes and cardiac function, with white blood cell count≥4.0×109/L, neutrophil count≥1.5×109/L, platelet count≥100×109/L, hemoglobin≥95g/L, serum bilirubin≤1.5 folds of upper normal limit, Alanine transaminase and glutamic oxalacetic transaminase ≤2 folds of upper normal limit, and serum creatinine≤1.5mg/dl.
  • Estimated survival time was above 3 months;
  • Patients who were well acknowledged of this study and signed the informed consent forms.

Exclusion Criteria:

  • Patients who received whole body treatment of metastatic gastric cancer previously;
  • Patients who underwent surgeries within 4 weeks before this study;
  • Patients who had allergic constitutions or were allergic to biological products of proteins and to any medicine used in this study;
  • Female patients in gestation or lactation period, or those who were interfile but received no contraception measures;
  • Patients who were with other symptoms unsuitable to this study;
  • Patients who were treated by other anti-tumor methods at that time;
  • Patients who had no measurable nidus;
  • Patients who had one of the following conditions: uncontrolled metastatic nidus in central nervous system, dysfunction of important organs, severe cardiac diseases (including congestive heart failure, uncontrollable arrhythmia, angina pectoris needed long-term drug treatment, valvular heart diseases and myocardial infarction), hypertension, women in gestation or lactation period, protracted infectious wound as well as uncontrollable psychosis history.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02008422


Locations
Layout table for location information
China, Xinjiang
Cancer Hospital of Xinjiang Medical University
Urumqi, Xinjiang, China, 830011
Sponsors and Collaborators
Tang Xushan
Investigators
Layout table for investigator information
Study Director: Tang Yong, Professor Cnacer Hospital of Xinjiang Medical University
Layout table for additonal information
Responsible Party: Tang Xushan, Xinjiang Medical University
ClinicalTrials.gov Identifier: NCT02008422    
Other Study ID Numbers: XinjiangMU (006)
First Posted: December 11, 2013    Key Record Dates
Last Update Posted: December 11, 2013
Last Verified: August 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Oxaliplatin
Tegafur
Endostar protein
Endostatins
Antineoplastic Agents
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors